fashion -WSS

fashion

author：Wikipedia 2025-09-29 00:38:58 - browse：2

A group of four doctors gather around a hologram projecting different medical icons — health tech coverage from STAT — Adobe

DarioHealth, which makes apps for managing chronic diseases, today announced it will acquire digital mental health company Twill for $10 million in cash plus stock valued at over $20 million at the end of Tuesday trading. The move is a bet that a consolidated offering can attract a critical mass of large customers in a market where profits have been elusive.

Founded in 2011, Dario started with a diabetes app targeted at consumers before expanding it to hypertension and weight management. It still maintains that direct-to-consumer business but has since shifted its focus to selling its suite of offerings, including a musculoskeletal care program it acquired in 2021, to health plans and employers in the hopes of reaching much larger patient populations. Recent updates aimed at making itself attractive to clients include a new offering built around popular, and expensive, GLP-1 weight loss drugs, and published real world data suggesting its tools can save clients money on downstream health care costs. With Twill, Dario adds a mental health app and related services, addressing a top demand of employers.

Despite momentum, DarioHealth, which is publicly traded, is unprofitable, and by its own estimations on earnings calls last year, it remained a ways from that milestone. Before acquiring Twill, the company said that it expected the whole business to break even at about $80 million in revenue — about four times the roughly $20 million it projected for 2023. In November, the company reported that it lost over $40 million in the first nine months of 2023.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
Next article： Dogs on Prozac: What pet anti

knowledge

WSS

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Ebola: Gilead Sciences antiviral shows promise as new treatment

Bird flu outbreak in cows is latest avian flu curveball

Orangutan used medicinal plant to treat wound, first time ever seen

After traumatic brain injury, life support decisions can use more time

Wikipedia

fashion

focus

Medical leaders decry Supreme Court decision on affirmative action

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

How to save PrEP access — and even expand it

Change Healthcare outage fallout shows need for new oversight

Jerome Adams on the need for new antivirals for Covid

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Psychedelics group wrestles with new pharma identity

First U.S. drug developed to treat liver disease MASH is approved

leisure time

Bird flu outbreak in cows is latest avian flu curveball

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Q&A: Jennifer Adair on making gene therapy available globally

Medicare coverage of Wegovy, once blocked, now looks possible

Bird flu outbreak in cows is latest avian flu curveball

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

hotspot

knowledge

knowledge

hotspot